Intercept Presents New Primary Biliary Cholangitis Data at AASLD 2015

Intercept Pharmaceuticals, Inc. ICPT today announced results from three studies in primary biliary cirrhosis, recently renamed primary biliary cholangitis (PBC), that will be presented at the American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®) in San Francisco, CA from November 14-16. The studies evaluate investigational use of obeticholic acid (OCA), Intercept's lead farnesoid X receptor (FXR) agonist, for the treatment of PBC, the epidemiology of PBC, and both patient and physician perceptions of PBC care. Taken together, the following oral and poster presentations provide more information about the unmet need and treatment goals for PBC. Clinical Epidemiology of Primary Biliary Cirrhosis based on a Large U.S. Laboratory Database: Incidence and Trends in Serum Alkaline Phosphatase In an oral presentation, researchers will share results from an analysis of a clinical database of more than 575,000 patients See full press release